Device-agnostic hypoxia detection software for overdose prediction and positive reversal monitoring
Active Project Grant Awarded Last action
- Award ID
- R43DA064271
- Recipient
-
Altrumed LLC UEI J8F3W4SWZ944
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $808,156
Award facts
- Assistance listing
- 93.279 Drug Use and Addiction Research Programs
- Completion date 72% complete
- Originally
- Place of performance
- Pennsylvania, USA
Award details come from USAspending.gov.
Description
- Abstract
- / project summary despite the availability of naloxone, opioid overdoses claim 84,181 lives annually in the U.S., with an additional hidden toll of non-fatal opioid overdoses (NFOO) leading to hypoxia-induced brain injuries. Opioid-induced respiratory depression (OIRD) remains the primary cause of hypoxia-related brain injuries, which can lead to long-term neurological impairments such as encephalopathy, cognitive deficits, and motor dysfunction. These injuries begin within four minutes of hypoxia onset, while EMS response times average over nine minutes. Furthermore, ~52% of overdoses occur when the individual is alone, and even in the presence of bystanders, 27% fail to recognize the difference between opioid use and a potentially fatal overdose. To address this, dove combines an innovative shoulder-wearable sensor with device-agnostic software to predict fatal overdoses and facilitate effective reversal interventions. Dove integrates advanced algorithms that analyze SPO2 levels, respiratory rates, and motion patterns, delivering real-time verbal feedback akin to an automated external defibrillator (AED). This guidance enables responders-whether harm reduction volunteers, EMS, or law enforcement-to administer tailored interventions, such as naloxone redosing or bag-valve-mask (BVM) ventilation. Importantly, dove addresses challenges posed by novel substances like xylazine, which impede respiratory recovery and render naloxone insufficient. BVM, a preferred alternative among 105 harm reduction stakeholders interviewed during NIH I-corps, offers a more humane and effective means of restoring oxygenation in complex overdose scenarios. The project encompasses a one-year phase I to build on our I-corps participation to validate commercialization potential. Phase I focuses on developing device-agnostic software for hypoxia monitoring and validating biomarkers for overdose prediction and reversal. This includes stakeholder feedback, feasibility analysis, and FDA guidance, laying the groundwork for phase II clinical trials.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $404,078 | |
| Original award | $404,078 |
Quick answers
Who received award R43DA064271?
R43DA064271 was awarded to Altrumed LLC by National Institute on Drug Abuse (National Institutes of Health) on August 15, 2025.
How much is award R43DA064271 worth?
$808,156 has been obligated on R43DA064271.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award